10-Q: TELA Bio Reports Q1 2025 Results: Revenue Up 12% but Net Loss Widens

Sentiment:

Quarterly Report 8 May 2025 4:30 PM

TELA Bio's first quarter 2025 revenue increased by 12% year-over-year, but the company's net loss also significantly increased due to various factors including the absence of a gain from the sale of a product line that occurred in the prior year.

Capital raiseThe company has an at-the-market offering program under which it may sell shares of its common stock, from time to time through Piper Sandler & Co, in an initial amount of up to $50 million.No sales were made under the Equity Agreement during the three months ended March 31, 2025.The company may seek to sell common or preferred equity or debt securities or enter into a new credit facility if its existing cash resources are insufficient to satisfy its liquidity requirements.

Worse than expectedThe net loss increased significantly from $5.7 million to $11.3 million year-over-year, indicating a deterioration in profitability.The absence of a $7.6 million gain from the sale of the NIVIS product line in Q1 2024 contributed to the increased net loss.

Summary

TELA Bio, Inc. reported its financial results for the quarter ended March 31, 2025.
Revenue increased by 12% to $18.5 million, compared to $16.6 million in the same period last year.
The company's net loss significantly widened to $11.3 million, or $0.25 per share, compared to a net loss of $5.7 million, or $0.23 per share, in the first quarter of 2024.
The increase in net loss is attributed to the absence of a $7.6 million gain from the sale of the NIVIS product line, which occurred in the first quarter of 2024.
Cost of revenue increased by 14% to $5.9 million, driven by higher unit sales and increased charges for excess and obsolete inventory.
Sales and marketing expenses decreased by 5% to $16.6 million due to lower compensation costs and consulting expenses.
Research and development expenses increased by 6% to $2.5 million due to higher study and development costs.
As of March 31, 2025, TELA Bio had cash and cash equivalents of $42.8 million and an accumulated deficit of $370.0 million.
The company believes its existing cash resources will be sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue increased, the net loss also increased significantly. The company believes it has enough cash for the next 12 months, but the increased loss and potential need for future capital raises temper any positive outlook.

Positives

Revenue increased by 12% year-over-year, driven by higher unit sales of hernia products and growing international sales.
Sales and marketing expenses decreased by 5% due to lower compensation costs and consulting expenses.
The company believes its existing cash resources will be sufficient to fund operations for at least the next 12 months.
OviTex unit sales increased by 29% year-over-year.
The company launched larger sizes of OviTex PRS in March 2025, which may reduce the need for multiple smaller pieces and simplify complex procedures.
The company launched OviTex IHR Reinforced Tissue Matrix in April 2024, specifically designed for robotic and laparoscopic inguinal hernia procedures.

Negatives

Net loss significantly increased to $11.3 million, compared to $5.7 million in the same period last year.
The increase in net loss is primarily due to the absence of a $7.6 million gain from the sale of the NIVIS product line in Q1 2024.
Cost of revenue increased by 14% due to higher unit sales and increased charges for excess and obsolete inventory.
OviTex PRS unit sales decreased by 3% year-over-year.
The company has an accumulated deficit of $370.0 million as of March 31, 2025.

Risks

Macroeconomic conditions, including economic uncertainty, cybersecurity events, supply chain disruptions, and inflationary pressures, could negatively impact the company's business.
The imposition of tariffs on imports from New Zealand could increase the cost of the company's products and adversely impact demand.
The company's ability to achieve and maintain adequate levels of coverage or reimbursement for its products is uncertain.
The company's reliance on a single direct sales force and exclusive contract manufacturer poses risks to its operations.
The company's indebtedness under the MidCap Credit Agreement could restrict its operations and ability to incur additional debt.
The company has incurred operating losses since inception and anticipates that its operating losses will continue in the near term.

Future Outlook

The company believes that its existing cash resources will be sufficient to meet its capital requirements and fund its operations for at least the next 12 months. The company intends to continue to make investments in research and development efforts to develop improvements and enhancements to its product portfolio.

Management Comments

The company is dedicated to building true partnerships with surgeons and healthcare providers to deliver solutions that provide both clinical and economic improvements.
The company believes that genuine collaboration with surgeons and healthcare providers results in the development of new solutions that empower patient care and addresses unmet needs within the soft tissue reconstruction market.

Industry Context

TELA Bio operates in the competitive soft-tissue reconstruction market, focusing on hernia repair and plastic and reconstructive surgery. The company competes with larger competitors and seeks to differentiate itself through its OviTex and OviTex PRS product lines, which combine biologic matrices and polymer materials. The company's growth strategy involves expanding its direct sales force, contracting with group purchasing organizations, and developing new products and indications.

Comparison to Industry Standards

The document does not provide enough information to make a detailed comparison to industry standards.
To compare TELA Bio to industry standards, we would need to analyze the performance of comparable companies in the soft-tissue reconstruction market, such as Allergan, Integra LifeSciences, and Medtronic.
Key metrics for comparison would include revenue growth, gross margin, operating expenses, and market share.
Additionally, we would need to assess the clinical outcomes and adoption rates of TELA Bio's products compared to competing products in the hernia repair and plastic and reconstructive surgery markets.
Without this additional information, it is difficult to determine whether TELA Bio's results are above, below, or in line with industry benchmarks.

Stakeholder Impact

Shareholders: The increased net loss may negatively impact shareholder value.
Employees: Potential for continued investment in sales, marketing, and R&D could provide job security and growth opportunities.
Customers: Continued product development and enhancements could lead to improved solutions for soft-tissue reconstruction.
Suppliers: Increased revenue could lead to higher demand for supplies and materials.
Creditors: The company's ability to meet its debt obligations depends on its financial performance and cash flow.

Next Steps

The company will continue to invest in sales and marketing initiatives to support growth in existing and new markets.
The company will continue to invest in research and development activities to develop improvements and enhancements to its product portfolio.
The company will continue to explore the development of lower-cost, higher-margin resorbable polymer-based devices targeting its current indications.
The company will continue to evaluate and finalize the clinical study protocol and anticipate additional FDA interactions related to such to support a pre-market application to obtain approval for an indication for OviTex PRS for use in breast reconstruction.

Key Dates

Date	Description
April 17, 2012	TELA Bio, Inc. was incorporated in the state of Delaware.
May 26, 2022	The Company entered into the Credit and Security Agreement with MidCap Financial Trust.
November 2023	The Company entered into an Equity Distribution Agreement with Piper Sandler & Co.
March 2024	The Company sold its distribution rights to MiMedx Group, Inc. for NIVIS.
April 2024	The company launched OviTex IHR Reinforced Tissue Matrix.
May 2024	The company received clearance of a Special 510(k) related to minor changes to our OviTex PRS Permanent and Short-Term Resorbable devices.
October 2024	The company received approval from the FDA for its investigational device exemption application relating to the study of the safety and effectiveness of our OviTex PRS product in implant-based breast reconstruction.
October 24, 2024	The company completed an underwritten public offering of common stock and pre-funded warrants.
December 2024	The company received clearance of a Special 510(k) related to two new additional large size product offerings in our OviTex PRS portfolio.
March 2025	The company announced the U.S. launch of larger sizes of OviTex PRS.
March 31, 2025	End of the financial reporting period for this 10-Q.
May 1, 2027	The MidCap term loan matures.
May 8, 2025	Date of report.

Keywords

TELA Bio, OviTex, OviTex PRS, Hernia Repair, Soft-Tissue Reconstruction, Financial Results, Revenue, Net Loss, Medical Technology, Aroa

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.